Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
DMPK Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
PLoS One. 2015 Dec 9;10(12):e0144675. doi: 10.1371/journal.pone.0144675. eCollection 2015.
Centromere-associated protein E (CENP-E) regulates both chromosome congression and the spindle assembly checkpoint (SAC) during mitosis. The loss of CENP-E function causes chromosome misalignment, leading to SAC activation and apoptosis during prolonged mitotic arrest. Here, we describe the biological and antiproliferative activities of a novel small-molecule inhibitor of CENP-E, Compound-A (Cmpd-A). Cmpd-A inhibits the ATPase activity of the CENP-E motor domain, acting as a time-dependent inhibitor with an ATP-competitive-like behavior. Cmpd-A causes chromosome misalignment on the metaphase plate, leading to prolonged mitotic arrest. Treatment with Cmpd-A induces antiproliferation in multiple cancer cell lines. Furthermore, Cmpd-A exhibits antitumor activity in a nude mouse xenograft model, and this antitumor activity is accompanied by the elevation of phosphohistone H3 levels in tumors. These findings demonstrate the potency of the CENP-E inhibitor Cmpd-A and its potential as an anticancer therapeutic agent.
着丝粒相关蛋白 E(CENP-E)在有丝分裂过程中调节染色体的向心性和纺锤体组装检查点(SAC)。CENP-E 功能的丧失导致染色体错位,导致 SAC 激活和长时间有丝分裂阻滞时的细胞凋亡。在这里,我们描述了一种新型 CENP-E 小分子抑制剂,化合物-A(Cmpd-A)的生物学和抗增殖活性。Cmpd-A 抑制 CENP-E 马达结构域的 ATP 酶活性,作为一种时变抑制剂,具有 ATP 竞争性样行为。Cmpd-A 导致中期板上的染色体错位,导致有丝分裂阻滞延长。用 Cmpd-A 处理可诱导多种癌细胞系的增殖抑制。此外,Cmpd-A 在裸鼠异种移植模型中表现出抗肿瘤活性,并且这种抗肿瘤活性伴随着肿瘤中磷酸组蛋白 H3 水平的升高。这些发现证明了 CENP-E 抑制剂 Cmpd-A 的效力及其作为抗癌治疗剂的潜力。